Tag:
Takeda Pharmaceutical
Latest Headlines
Latest Headlines
Sales-needy Takeda springs for emerging markets growth
Takeda Pharmaceuticals hopes to ease its suffering with a little emerging markets medicine.
Open source sizzles in biotech sphere
Recent efforts in biomedicine have made progress with strategies and structures that borrow heavily from the open source movement in software development.
Amylin's up for bid. Who'll step in line?
Step right up, Big Pharma bidders. Amylin Pharmaceuticals is up for auction.
Takeda backs analysis of genomic data on brain diseases
Major players in genomic research and mental health recently formed the CommonMind Consortium to analyze large-scale genomic data and make the findings publicly available to researchers online.
Takeda snaps up URL Pharma in $800M+ deal
The Japanese company is buying the Philadelphia-based pharma for $800 million upfront, plus potential follow-up payments.
Judge chooses lead lawyers in Actos litigation
Two plaintiffs' lawyers experienced in pharma liability litigation have been tapped to lead the group managing thousands of suits alleging that Takeda Pharmaceutical's diabetes drug Actos caused bladder cancer, Bloomberg reports.
Whistleblower claims Takeda blunted Actos heart reports
Did Takeda Pharmaceutical downplay reports of heart failure in Actos patients?
GSK, Takeda say nay to in-house diagnostics units
GlaxoSmithKline ( $GSK ) and Takeda Pharmaceutical are choosing the partnerships side of the divide when it comes to developing diagnostics to team up with their drugs. Both companies have said they're
Takeda opens new drug development center in China
Japan's Takeda is adding a new drug development center in Shanghai intended to complement the international clinical work now under way in Singapore and Cambridge, MA. Both of the existing...
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
